H
2.31
-0.05 (-2.12%)
| Previous Close | 2.36 |
| Open | 2.40 |
| Volume | 2,648,367 |
| Avg. Volume (3M) | 4,989,145 |
| Market Cap | 358,324,896 |
| Price / Sales | 257.78 |
| Price / Book | 61.75 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Operating Margin (TTM) | -4,484.33% |
| Diluted EPS (TTM) | -0.690 |
| Total Debt/Equity (MRQ) | 228.93% |
| Current Ratio (MRQ) | 3.68 |
| Operating Cash Flow (TTM) | -99.38 M |
| Levered Free Cash Flow (TTM) | -67.40 M |
| Return on Assets (TTM) | -42.82% |
| Return on Equity (TTM) | -249.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Humacyte, Inc. | Bearish | Bearish |
AIStockmoo Score
-1.7
| Analyst Consensus | 1.0 |
| Insider Activity | -5.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -1.70 |
|
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 20.16% |
| % Held by Institutions | 40.20% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (D. Boral Capital, 982.25%) | Buy |
| Median | 3.50 (51.52%) | |
| Low | 3.00 (HC Wainwright & Co., 29.87%) | Buy |
| Average | 8.75 (278.79%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 1.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 27 Aug 2025 | 3.50 (51.52%) | Buy | 1.53 |
| HC Wainwright & Co. | 12 Aug 2025 | 3.00 (29.87%) | Buy | 1.80 |
| TD Cowen | 12 Aug 2025 | 3.50 (51.52%) | Buy | 1.80 |
| D. Boral Capital | 11 Aug 2025 | 25.00 (982.25%) | Buy | 1.75 |
| 23 Jul 2025 | 25.00 (982.25%) | Buy | 2.73 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DOUGAN BRADY W | - | 1.68 | -2,241,045 | -3,707,795 |
| NIKLASON LAURA E | - | 1.68 | -2,241,045 | -3,707,795 |
| Aggregate Net Quantity | -4,482,090 | |||
| Aggregate Net Value ($) | -7,415,589 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 1.68 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NIKLASON LAURA E | Officer | 20 Aug 2025 | Sell (-) | 591,685 | 1.63 | 964,447 |
| DOUGAN BRADY W | Director | 20 Aug 2025 | Sell (-) | 591,685 | 1.63 | 964,447 |
| NIKLASON LAURA E | Officer | 19 Aug 2025 | Sell (-) | 1,100,000 | 1.60 | 1,754,500 |
| DOUGAN BRADY W | Director | 19 Aug 2025 | Sell (-) | 1,100,000 | 1.60 | 1,754,500 |
| NIKLASON LAURA E | Officer | 18 Aug 2025 | Sell (-) | 549,360 | 1.80 | 988,848 |
| DOUGAN BRADY W | Director | 18 Aug 2025 | Sell (-) | 549,360 | 1.80 | 988,848 |
| Date | Type | Details |
|---|---|---|
| 11 Aug 2025 | Announcement | Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update |
| 23 Jul 2025 | Announcement | Humacyte Announces First Symvess™ Sale to Military Treatment Facility |
| 08 Jul 2025 | Announcement | Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency |
| 09 Jun 2025 | Announcement | Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting |
| 02 Jun 2025 | Announcement | Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |